Veloxis Pharmaceuticals

    OverviewSuggest Edit

    Veloxis Pharmaceuticals is a biopharmaceutical company, which identifies, develops, and commercializes products that are used in transplantation and adjacent therapies. The Company's patented delivery technology, MeltDose, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis's lead product candidate is Envarsus XR, a once-daily dosage tablet version of tacrolimus, which is used to aid in the prophylaxis of organ rejection in transplant recipients.

    TypePublic
    Founded2002
    HQKøbenhavn, DK
    Websiteveloxis.com

    Latest Updates

    Employees (est.) (Feb 2019)54
    Cybersecurity ratingCMore

    Key People/Management at Veloxis Pharmaceuticals

    Craig Collard

    Craig Collard

    CEO
    Masaya Etoh

    Masaya Etoh

    Chairman
    Alastair McEwan

    Alastair McEwan

    Chief Operations Officer
    Ira Duarte

    Ira Duarte

    Chief Financial Officer
    Daisuke Matsuo

    Daisuke Matsuo

    Board Member
    Ulf Meier-Kriesche

    Ulf Meier-Kriesche

    Chief Scientific Officer
    Show more

    Veloxis Pharmaceuticals Office Locations

    Veloxis Pharmaceuticals has offices in København and Cary
    København, DK (HQ)
    37 Amerika Pl.
    Cary, US
    1001 Winstead Dr #310
    Show all (2)

    Veloxis Pharmaceuticals Financials and Metrics

    Veloxis Pharmaceuticals Cybersecurity Score

    Cybersecurity ratingPremium dataset

    C

    77/100

    SecurityScorecard logo

    Veloxis Pharmaceuticals Online and Social Media Presence

    Embed Graph

    Veloxis Pharmaceuticals Blogs

    Meddelelse om Tvangsindløsning til Aktionærerne i Veloxis Pharmaceuticals A/S

    Selskabsmeddelelse nr. 9/2020 Til: NASDAQ Copenhagen A/S København, Danmark, fredag den 24. januar 2020   Meddelelse om Tvangsindløsning til Aktionærerne i Veloxis Pharmaceuticals A/S   Asahi Kasei Pharma Denmark A/S har fremsendt meddelelse om tvangsindløsning til aktionærerne i Veloxis

    Veloxis Pharmaceuticals A/S: Offentliggørelse af Storaktionærmeddelelser

    Veloxis Pharmaceuticals A/S: Offentliggørelse af Storaktionærmeddelelser Greta.Jankausk… Fri, 01/24/2020 - 15:27 Veloxis Pharmaceuticals A/S: Offentliggørelse af Storaktionærmeddelelser January 24, 2020 at 3:22 PM CET This release is a backfill from a News Wir…

    Veloxis Forhøjer Aktiekapitalen i forbindelse med Asahi Kasei Pharma Denmarks Udnyttelse af Warrants Erhvervet under det Offentlige Købstilbud

    Veloxis Forhøjer Aktiekapitalen i forbindelse med Asahi Kasei Pharma Denmarks Udnyttelse af Warrants Erhvervet under det Offentlige Købstilbud jo-en.bautista… Thu, 01/23/2020 - 20:22 Veloxis Forhøjer Aktiekapitalen i forbindelse med Asahi Kasei Pharma Denmarks Udnyttelse af Warrants Erhver…

    Veloxis Increases Share Capital in Connection with Asahi Kasei Pharma Denmark's Exercise of Warrants Acquired under the Public Tender Offer

    Veloxis Increases Share Capital in Connection with Asahi Kasei Pharma Denmark's Exercise of Warrants Acquired under the Public Tender Offer Content Import Thu, 01/23/2020 - 19:59 Veloxis Increases Share Capital in Connection with Asahi Kasei Pharma Denmark's Exercise of Warrants Acquired u…

    Veloxis Increases Share Capital in Connection with Asahi Kasei Pharma Denmark's Exercise of Warrants Acquired under the Public Tender Offer

    Company Release no. 7/2020 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, Thursday 23 January 2020 Veloxis Increases Share Capital in Connection with Asahi Kasei Pharma Denmark's Exercise of Warrants Acquired under the Public Tender Offer On 17

    Veloxis Forhøjer Aktiekapitalen i forbindelse med Asahi Kasei Pharma Denmarks Udnyttelse af Warrants Erhvervet under det Offentlige Købstilbud

    Selskabsmeddelelse nr. 7/2020 Til: NASDAQ Copenhagen A/S                                                  København, Danmark, torsdag den 23. januar 2020   Veloxis Forhøjer Aktiekapitalen i forbindelse med Asahi Kasei Pharma Denmarks Udnyttelse af Warrants Erhvervet under det Offentlige Købstilbud
    Show more

    Veloxis Pharmaceuticals Frequently Asked Questions

    • When was Veloxis Pharmaceuticals founded?

      Veloxis Pharmaceuticals was founded in 2002.

    • Who are Veloxis Pharmaceuticals key executives?

      Veloxis Pharmaceuticals's key executives are Craig Collard, Masaya Etoh and Alastair McEwan.

    • How many employees does Veloxis Pharmaceuticals have?

      Veloxis Pharmaceuticals has 54 employees.

    • Who are Veloxis Pharmaceuticals competitors?

      Competitors of Veloxis Pharmaceuticals include Retrophin, Palatin Technologies and Genoa Pharmaceuticals.

    • Where is Veloxis Pharmaceuticals headquarters?

      Veloxis Pharmaceuticals headquarters is located at 37 Amerika Pl., København.

    • Where are Veloxis Pharmaceuticals offices?

      Veloxis Pharmaceuticals has offices in København and Cary.

    • How many offices does Veloxis Pharmaceuticals have?

      Veloxis Pharmaceuticals has 2 offices.